Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

A bumper rally in European stocks appears to be slowing, putting Wall Street in the lead again after a lopsided U.S.-EU trade ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had expected to see as of May. The company also said it now expec ...

COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of ...

Shares in Asia are mixed after the U.S. and China ended their latest round of trade talks without a deal. U.S, futures edged ...

NHS set to reveal impact of strike action as doctors return to work Disruption across the NHS in England caused by resident ...

Wall Street’s weeklong, record-breaking run ran out of momentum. The S&P 500 slipped 0.3% Tuesday for its first drop after ...